Specific requirements for translation of biological research into clinical radiation oncology-Reference-Cited by-同舟云学术

Specific requirements for translation of biological research into clinical radiation oncology

Published:2020-04-08 Issue:7 Volume:14 Page:1569-1576
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Krause Mechthild¹²³⁴⁵^ORCID,Alsner Jan⁶,Linge Annett¹²³⁴⁷,Bütof Rebecca¹²³⁴⁷,Löck Steffen¹²³⁴⁷,Bristow Rob⁸

Affiliation:

1. German Cancer Consortium (DKTK) Partner Site Dresden Germany

2. German Cancer Research Center (DKFZ) Heidelberg Germany

3. OncoRay ‐ National Center for Radiation Research in Oncology Faculty of Medicine University Hospital Carl Gustav Carus Helmholtz‐Zentrum Dresden – Rossendorf TU Dresden Germany

4. Department of Radiotherapy and Radiation Oncology Faculty of Medicine University Hospital Carl Gustav Carus TU Dresden Germany

5. Helmholtz‐Zentrum Dresden ‐ Rossendorf Institute of Radiooncology – OncoRay Dresden Germany

6. Department of Experimental Clinical Oncology Aarhus University Hospital Denmark

7. National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), HeidelbergGermany; Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, DresdenGermany, and; Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR) Dresden Germany

8. Translational Oncogenomics CRUK Manchester Institute and Centre Division of Cancer Sciences University of Manchester UK

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12671

Reference39 articles.

1. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

2. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

3. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

4. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

5. Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med. 2017, 7, 1

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia Imaging Markers and Their Potential Roles in Radiotherapy;Nuclear Medicine Seminars;2023-11-01

2. Letter to the Editor of Radiotherapy and Oncology regarding the paper entitled “50 years of radiotherapy research: Evolution, trends and lessons for the future” by Berger et al. (December 2021, Volume 165);Radiotherapy and Oncology;2022-07

3. Models for Translational Proton Radiobiology—From Bench to Bedside and Back;Cancers;2021-08-22

4. Radiation Oncology – Towards a mission‐oriented approach to cancer;Molecular Oncology;2020-07

5. Role of radiation oncology in modern multidisciplinary cancer treatment;Molecular Oncology;2020-06-22